What it is
Syn-Ake is a trade name for a small synthetic molecule used in anti-wrinkle creams. On an ingredient list it appears as dipeptide diaminobutyroyl benzylamide diacetate. PubChem records it as CID 71465152 (read 2026-11-17):
| Property | Value | Source |
|---|---|---|
| Building blocks | Beta-alanine · proline · 2,4-diaminobutyric acid, ending in a benzylamide | PubChem chemical name |
| Formula (diacetate salt) | C23H37N5O7 | PubChem CID 71465152 |
| Molecular weight (diacetate) | 495.6 | PubChem |
| Formula (without the two acetates) | C19H29N5O3, about 375.5 | Our calculation |
| Origin | Synthetic | — |
"Dipeptide" in the name undersells and oversells at once. Reading the PubChem name, the chain has three building blocks, not two — but only proline is one of the twenty standard amino acids in proteins. Beta-alanine and diaminobutyric acid are non-standard, and the end is capped with a benzyl group rather than a normal peptide end (our reading of the name). It is peptide-like rather than a classic peptide.
The venom it imitates
The molecule was designed using waglerin-1 as a template — a toxin of Wagler's pit viper, Tropidolaemus wagleri. A 2017 paper on the toxin's evolution names the connection in its title: the waglerin peptides used in anti-wrinkle skin cream (Debono et al., J Mol Evol, PMID 27864608).
UniProt's record for the precursor (P24335, read 2026-11-17) gives waglerin-1 as 22 amino acids, GGKPDLRPCHPPCHYIPRPKPR, cut from a 24-residue chain. Set the two side by side and the cosmetic is not a fragment of the toxin: it is a three-unit synthetic, about a sixth the length (our comparison). The resemblance claimed is in how it is meant to act, not in its sequence.
Waglerin-1 selectively blocks the epsilon subunit of the muscle nicotinic acetylcholine receptor (UniProt P24335), the receptor that receives the nerve's signal to contract. UniProt adds that in mice it causes rapid collapse and spasms, while rats show no toxic effect on breathing or blood pressure — a reminder that a toxin's action differs by species. The cosmetic idea is that a molecule acting there could soften the repeated small contractions behind expression lines. No study found tonight tested this molecule at that receptor.
What PubMed holds
A search under the trade name and the INCI name on 2026-11-17 returned three records:
| Year | Journal | What was done | Isolates Syn-Ake's own effect? |
|---|---|---|---|
| 2024 | J Biomol Struct Dyn (PMID 37349941) | Computer docking against collagen-breaking MMP enzymes and SIRT1; antioxidant, cytotoxicity and Ames mutagenicity tests in the laboratory | In vitro only |
| 2026 | Int J Cosmet Sci (PMID 41668671) | L'Oréal serum with acetyl hexapeptide-8, this peptide, gluconolactone, niacinamide and laminaria extract; skin explants plus clinical studies of 50 and 42 people over 12 weeks | No — five actives together |
| 2026 | 3 Biotech (PMID 42927054) | A nanoemulsion containing "peptide acting on neurotransmitters" (title; not read) | Not read |
The 2026 serum study reports static-wrinkle clinical scores improving by 35% to 69% and dynamic wrinkles by 10% to 13% after 12 weeks (all P < 0.001). Its abstract describes no vehicle or placebo arm in the clinical studies, and the authors are L'Oréal researchers testing their own formula. With five actives in one serum, the result cannot be assigned to any one of them.
For scale: PubMed holds the three records above for this ingredient, while "waglerin" — the toxin it imitates — returns 20 when searched the same way.
Where it stands
Syn-Ake is a cosmetic ingredient, not a drug, and is not listed in Drugs@FDA. The library's Argireline entry covers the other "Botox-like" cosmetic peptide that shared the 2026 serum, and SNAP-8 its longer relative. PeptideGlowJournal's Syn-Ake ingredient page reads the ingredient in finished products; this entry stops at the molecule and its record.
Sources opened 2026-11-17: PubChem CID 71465152; UniProt P24335; Gok et al. 2024 (PMID 37349941); Zhu et al. 2026 (PMID 41668671); Debono et al. 2017 (PMID 27864608, record); 3 Biotech 2026 (PMID 42927054, title); PubMed E-utilities and ClinicalTrials.gov API v2 counts.
